AUSTIN, Texas, Luminex Corporation (Nasdaq: LMNX – News) today announced the immediate availability of the Luminex 200, the latest advancement of Luminex’s line of microsphere-based multiplexed detection instruments based on the Company’s proprietary xMAP® technology.

The Luminex 200 is designed to meet the multiplexed testing needs of the clinical and research laboratory professional. The Luminex 200 further solidifies the established leadership of Luminex in both nucleic acid- and protein-based multiplexing technology by incorporating features that further enhance ease of use for the end-users. In addition, the Luminex 200 is designed around the same xMAP technology as the Luminex 100, enabling customers who upgrade to this system to continue to use applications validated on earlier Luminex systems.

Luminex CEO, Patrick J. Balthrop stated, “All of us at Luminex are pleased to deliver this exciting new instrument platform to the market. With over 3000 Luminex instruments sold to date, we have established a clear leadership position in bead-based multiplexing. The newly designed Luminex 200 brings reliability and ease-of-use to even higher levels. Our partners have all expressed excitement about launching this new product to complement their ever-growing applications menus.”

For more information about the Luminex 200 and xMAP technology, please see www.luminexcorp.com. The Luminex 200 will be on display at Luminex’s xSamples Amsterdam, a European users seminar (see www.xsamples.com ) September 28 – 29, 2005.

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex’s ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company’s operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact: Harriss T. Currie

Vice President, Finance

Chief Financial Officer

512.219.8020

[email protected]